首页> 外文期刊>The Journal of Antimicrobial Chemotherapy >Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009).
【24h】

Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009).

机译:新型口服脂质基制剂(iCo-009)多次给药后,两性霉素B在小鼠中的生物分布和组织毒性。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: The purpose of this study was to assess the biodistribution and toxicity of amphotericin B (AMB) following multiple dose administration of an oral lipid-based formulation (iCo-009). METHODS: BALB/c female mice were used. ICo-009 was administered twice daily for 5 days at doses of 2.5-20 mg/kg. Untreated animals, oral vehicle or intravenous Fungizone(R) (1 or 2 mg/kg) served as control groups. The animals were sacrificed 12 h following the last administration of AMB, and blood and multiple tissues were harvested for drug analysis and histopathological evaluation. Plasma or tissue samples were analysed for concentrations of AMB or creatinine by means of HPLC-UV. RESULTS: A dose-dependent accumulation of AMB in liver, spleen, kidney and lung tissues was found. The concentration of the drug in all these organs exceeded the corresponding concentrations in plasma at the same dose. The concentrations of AMB in heart and brain were similar to the corresponding concentrations in plasma. Creatinine concentrations were elevated above normal concentrations in the 2 mg/kg Fungizone(R) group only. Histopathological analysis of kidney and liver tissues revealed a normal pattern in all treated groups, except the 2 mg/kg Fungizone(R) group. No gastrointestinal toxicity was found in this study. CONCLUSIONS: A multiple dose treatment regimen with iCo-009 in mice results in a gradual accumulation of AMB in tissues. Despite significant concentrations of AMB, no kidney or liver toxicity of orally administered AMB was detected in this study. Furthermore, multiple oral administration of iCo-009 or of vehicle control did not induce gastrointestinal toxicity.
机译:目的:本研究的目的是评估多剂量口服脂质基制剂(iCo-009)后两性霉素B(AMB)的生物分布和毒性。方法:使用BALB / c雌性小鼠。 ICo-009以2.5-20 mg / kg的剂量每天两次给药,共5天。对照组为未经治疗的动物,口服赋形剂或静脉内Fungizone(1或2mg / kg)。最后一次施用AMB后12小时处死动物,并收集血液和多个组织用于药物分析和组织病理学评估。通过HPLC-UV分析血浆或组织样品中AMB或肌酸酐的浓度。结果:发现AMB在肝,脾,肾和肺组织中呈剂量依赖性积累。在相同剂量下,所有这些器官中药物的浓度均超过血浆中的相应浓度。心脏和大脑中AMB的浓度与血浆中相应的浓度相似。仅在2 mg / kg Fungizone?组中,肌酐浓度升高至高于正常浓度。肾脏和肝组织的组织病理学分析显示,除2 mg / kg Fungizone?组外,所有治疗组的形态均正常。在这项研究中未发现胃肠道毒性。结论:iCo-009在小鼠中的多剂量治疗方案导致AMB在组织中逐渐积累。尽管AMB浓度很高,但在这项研究中未检测到口服AMB的肾脏或肝脏毒性。此外,iCo-009的多次口服给药或载体对照均未引起胃肠道毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号